Please login to the form below
elranatamab
This page shows the latest elranatamab news and features for those working in and with pharma, biotech and healthcare.
Pfizer shares updated pivotal phase 2 elranatamab data for multiple myeloma
safety of elranatamab, and will continue to evaluate its potential benefits through the MagnetisMM clinical trial programme across earlier and broader populations, including newly diagnosed patients.”. ... granted elranatamab Fast Track Designation and
Latest news
-
Pfizer’s multiple myeloma treatment granted FDA Breakthrough Therapy Designation
Elranatamab-treated patients achieved an overall response rate of 61% in a phase 2 trial. ... The UK Medicines and Healthcare Products Regulatory Agency has also granted elranatamab Innovative Medicine Designation and the Innovation Passport, also for
-
Pfizer pauses enrolment for trial evaluating anti-BCMA bispecific antibody
We are highly encouraged by early data with subcutaneous elranatamab, which was discovered and developed at Pfizer and designed to enhance safety and convenience,” he added. ... Although Pfizer has paused enrolment into the trial, the company
More from news
Approximately 3 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Senior Medical Writer
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- AstraZeneca’s mild combination asthma reliever approved in UK
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis
- Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD
- When to call in the specialists: strategy in Medical Affairs
- Time to talk about health inequalities
- Powering Rapid Cognitive Analysis with AI
- AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma
PMHub
Wave Healthcare Communications
Wave combine scientific, medical and brand expertise to deliver clinically focused programmes that are trusted by HCPs, drive better patient...
Latest intelligence
- Time to talk about health inequalities
- Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
